Yunzhan Ning

Yunzhan Ning

Auto-generated profile, based on publicly available information

Yunzhan Ning

Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, Vienna 1090, Austria

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GTGuangzong Tian
Guangzong Tian
JHJing Hu
Jing Hu
CQChunjun Qin
Chunjun Qin
LLLingxin Li
Lingxin Li
YNYunzhan Ning
Yunzhan Ning
JYJian Yin
Jian Yin

30 April 2024 in Chemistry – A European Journal
Verified
Journal Article
Open access
JLJonathan Lefèbre
Jonathan Lefèbre
TFTorben Falk
Torben Falk
YNYunzhan Ning
Yunzhan Ning
CRChristoph Rademacher
Christoph Rademacher
C‐type lectins are a large superfamily of proteins involved in a multitude of biological processes. In particular, their involvement in immunity and homeostasis has rendered them attractive targets for diverse therapeutic interventions. They share a characteristic C‐type lectin‐like domain whose adaptability enables them to bind a broad spectrum of ligands beyond the originally defined canonical Ca2+‐dependent carbohydrate binding. Together with variable domain architecture and high‐level conformational plasticity, this enables C‐type lectins to meet diverse functional demands. Secondary sites provide another layer of regulation and are often intricately linked to functional diversity. Located remote from the canonical primary binding site, secondary sites can accommodate ligands with other physicochemical properties and alter protein dynamics, thus enhancing selectivity and enabling fine‐tuning of the biological response. In this review, we outline the structural determinants allowing C‐type lectins to perform a large variety of tasks and to accommodate the ligands associated with it. Using the six well‐characterized Ca2+‐dependent and Ca2+‐independent C‐type lectin receptors DC‐SIGN, langerin, MGL, dectin‐1, CLEC‐2 and NKG2D as examples, we focus on the characteristics of non‐canonical interactions and secondary sites and their potential use in drug discovery endeavors.

19 November 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YNYunzhan Ning
Yunzhan Ning
NENina-Louisa Efrém
Nina-Louisa Efrém
MAMachoud Amoussa
Machoud Amoussa
ETErtan Turhan
Ertan Turhan
DZDazhong Zheng
Dazhong Zheng
CRChristoph Rademacher
Christoph Rademacher
C-Type lectins are a large family of carbohydrate-binding proteins. Langerin is a member of this family and is expressed by Langerhans cells, involved in pathogen recognition and innate immune activation, making it a target for small-molecule modulation in immunology and infectious diseases. We previously identified thiazolopyrimidinones as a series of allosteric inhibitors, but the underlying mechanism remained unclear. In this study, 43Ca NMR demonstrated that these fragments induce Ca2+ release from the receptor. Our ITC data suggested a competitive relationship between inhibitors and Ca2+, which was further validated by 19F NMR spectroscopy showing inhibition of carbohydrate binding. Surprisingly, the fragment binding site was found to be located beneath the long loop, which supports the dynamic nature of the long loop being highly Ca2+ dependent. Our findings provide insight into the novel Ca2+-competitive inhibitory mechanism of murine langerin and are the first report on such an inhibitory mechanism for a C-type lectin.